<p>BioCryst 制药公司（NASDAQ:BCRX - 获取免费报告）董事 Theresa Heggie 于 8 月 13 日星期三出售了 70,000 股 BioCryst 制药股票。该股票的平均售价为 8.51 美元，总价值为 595,700.00 美元。出售后，该董事持有公司 65,352 股股票，估值约为 556,145.52 美元。这笔交易代表了他们持股比例的 51.72% 的减少。该交易已在与 SEC 的法律文件中披露，相关信息可通过 SEC 网站获取。</p>
<h2>BioCryst 制药股票表现</h2>
<p>NASDAQ:BCRX 在星期五开盘价为 8.45 美元。该公司的 50 日简单移动平均线为 9.11 美元，200 日简单移动平均线为 8.77 美元。BioCryst 制药公司 52 周低点为 6.01 美元，52 周高点为 11.31 美元。该股票的市值为 17.7 亿美元，市盈率为-46.94，市盈增长比率为 1.94，贝塔值为 1.10。</p>
<p>BioCryst 制药公司（NASDAQ:BCRX - 获取免费报告）于 8 月 4 日星期一发布了其财报。该生物技术公司报告本季度每股收益为 0.15 美元，超出分析师一致预期的 0.03 美元，超出幅度为 0.12 美元。该公司本季度的收入为 1.6335 亿美元，而分析师预期为 1.4959 亿美元。公司的收入同比增长 49.5%。在去年同期，该公司每股收益为-0.06 美元。研究分析师平均预测 BioCryst 制药公司本年度将发布-0.36 美元的每股收益。</p>
<h2>分析师设定新目标价</h2>
<p>一些股票研究分析师最近对 BCRX 股票进行了评估。美国银行在 7 月 1 日的报告中将 BioCryst 制药的目标价从 13.00 美元上调至 15.00 美元，并给予该公司 “买入” 评级。加拿大皇家银行在 6 月 30 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 BioCryst 制药的目标价为 13.00 美元。华尔街 Zen 在 7 月 26 日的报告中将 BioCryst 制药的评级从 “买入” 上调至 “强力买入”。Cantor Fitzgerald 在 4 月 29 日的研究报告中开始覆盖 BioCryst 制药，给予 “增持” 评级和 20.00 美元的目标价。最后，摩根大通在 5 月 6 日的研究报告中将 BioCryst 制药的目标价从 10.00 美元上调至 13.00 美元，并给予该公司 “增持” 评级。一位分析师对该股票给予持有评级，九位分析师给予买入评级，一位分析师给予强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，共识目标价为 16.70 美元。</p>
<p><strong>阅读我们最新的 BCRX 股票报告</strong></p>
<h2>BioCryst 制药的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近对 BCRX 的持仓进行了调整。Headlands Technologies LLC 在第一季度购买了 BioCryst 制药的新头寸，价值 32,000 美元。GF Fund Management CO. LTD.在第四季度购买了 BioCryst 制药的新股份，价值约 33,000 美元。GAMMA Investing LLC 在第一季度将其在 BioCryst 制药的持股增加了 1,161.8%。GAMMA Investing LLC 现在拥有 5,918 股该生物技术公司的股票，价值 44,000 美元，此前在上一季度又收购了 5,449 股。New Age Alpha Advisors LLC 在第一季度购买了 BioCryst 制药的新头寸，价值约 62,000 美元。最后，Family Legacy Financial Solutions LLC 在第二季度收购了 BioCryst 制药的新股份，价值约 72,000 美元。对冲基金和其他机构投资者持有该公司 85.88% 的股票。</p>
<h2>BioCryst 制药公司简介</h2>
<p>（获取免费报告）</p>
<p>BioCryst 制药公司是一家生物技术公司，开发口服小分子和蛋白质治疗药物以治疗罕见疾病。该公司销售 peramivir 注射液，这是一种用于治疗急性非复杂流感的静脉注射神经氨酸酶抑制剂，品牌名为 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及 ORLADEYO，一种用于治疗遗传性血管性水肿的口服丝氨酸蛋白酶抑制剂。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 BioCryst 制药更好</li>
<li>国会股票交易跟踪</li>
<li>3 只长期分红股票，价格低于 50 美元</li>
<li>你应该投资于便士股票吗？</li>
<li>AEP 如何成为关键的 AI 基础设施投资</li>
<li>股票中的死亡交叉是什么？</li>
<li>彼得·蒂尔支持的加密交易所 Bullish 的 IPO 进展如何？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 BioCryst 制药吗？</h2>
<p>在考虑 BioCryst 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 BioCryst 制药并不在名单上。</p>
<p>虽然 BioCryst 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BioCryst制药

<p>Theresa Heggie，BioCryst Pharmaceuticals, Inc.（纳斯达克股票代码：BCRX）的董事，于 8 月 13 日出售了 70,000 股公司股票，交易金额为 595,700 美元，平均价格为 8.51 美元。此次出售使她的持股减少了 51.72%，剩余 65,352 股，估值约为 556,145.52 美元。该交易已向美国证券交易委员会（SEC）披露。BioCryst 的股票开盘价为 8.45 美元，市值为 17.7 亿美元，最近的财报显示同比收入增长 49.5%</p>

<p>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>BioCryst 制药公司（NASDAQ:BCRX - 获取免费报告）董事 Theresa Heggie 于 8 月 13 日星期三出售了 70,000 股 BioCryst 制药股票。该股票的平均售价为 8.51 美元，总价值为 595,700.00 美元。出售后，该董事持有公司 65,352 股股票，估值约为 556,145.52 美元。这笔交易代表了他们持股比例的 51.72% 的减少。该交易已在与 SEC 的法律文件中披露，相关信息可通过 SEC 网站获取。</p>
</div><h2>BioCryst Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>BioCryst 制药股票表现</h2>
</div><p>NASDAQ:BCRX opened at $8.45 on Friday. The company's 50-day simple moving average is $9.11 and its 200-day simple moving average is $8.77. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $11.31. The stock has a market capitalization of $1.77 billion, a P/E ratio of -46.94, a P/E/G ratio of 1.94 and a beta of 1.10.</p>
<div class="lb-trans"><p>NASDAQ:BCRX 在星期五开盘价为 8.45 美元。该公司的 50 日简单移动平均线为 9.11 美元，200 日简单移动平均线为 8.77 美元。BioCryst 制药公司 52 周低点为 6.01 美元，52 周高点为 11.31 美元。该股票的市值为 17.7 亿美元，市盈率为-46.94，市盈增长比率为 1.94，贝塔值为 1.10。</p>
</div><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analysts' expectations of $149.59 million. The company's revenue was up 49.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.</p>
<div class="lb-trans"><p>BioCryst 制药公司（NASDAQ:BCRX - 获取免费报告）于 8 月 4 日星期一发布了其财报。该生物技术公司报告本季度每股收益为 0.15 美元，超出分析师一致预期的 0.03 美元，超出幅度为 0.12 美元。该公司本季度的收入为 1.6335 亿美元，而分析师预期为 1.4959 亿美元。公司的收入同比增长 49.5%。在去年同期，该公司每股收益为-0.06 美元。研究分析师平均预测 BioCryst 制药公司本年度将发布-0.36 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of equities research analysts recently weighed in on BCRX shares. Bank of America lifted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, July 1st. Royal Bank Of Canada reaffirmed an &#34;outperform&#34; rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, July 26th. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an &#34;overweight&#34; rating and a $20.00 price objective on the stock. Finally, JPMorgan Chase &amp; Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and a consensus price target of $16.70.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 BCRX 股票进行了评估。美国银行在 7 月 1 日的报告中将 BioCryst 制药的目标价从 13.00 美元上调至 15.00 美元，并给予该公司 “买入” 评级。加拿大皇家银行在 6 月 30 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 BioCryst 制药的目标价为 13.00 美元。华尔街 Zen 在 7 月 26 日的报告中将 BioCryst 制药的评级从 “买入” 上调至 “强力买入”。Cantor Fitzgerald 在 4 月 29 日的研究报告中开始覆盖 BioCryst 制药，给予 “增持” 评级和 20.00 美元的目标价。最后，摩根大通在 5 月 6 日的研究报告中将 BioCryst 制药的目标价从 10.00 美元上调至 13.00 美元，并给予该公司 “增持” 评级。一位分析师对该股票给予持有评级，九位分析师给予买入评级，一位分析师给予强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，共识目标价为 16.70 美元。</p>
</div><p><strong>Read Our Latest Stock Report on BCRX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 BCRX 股票报告</strong></p>
</div><h2>Institutional Trading of BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>BioCryst 制药的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Headlands Technologies LLC purchased a new position in BioCryst Pharmaceuticals during the 1st quarter worth $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. GAMMA Investing LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $62,000. Finally, Family Legacy Financial Solutions LLC acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth approximately $72,000. Hedge funds and other institutional investors own 85.88% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 BCRX 的持仓进行了调整。Headlands Technologies LLC 在第一季度购买了 BioCryst 制药的新头寸，价值 32,000 美元。GF Fund Management CO. LTD.在第四季度购买了 BioCryst 制药的新股份，价值约 33,000 美元。GAMMA Investing LLC 在第一季度将其在 BioCryst 制药的持股增加了 1,161.8%。GAMMA Investing LLC 现在拥有 5,918 股该生物技术公司的股票，价值 44,000 美元，此前在上一季度又收购了 5,449 股。New Age Alpha Advisors LLC 在第一季度购买了 BioCryst 制药的新头寸，价值约 62,000 美元。最后，Family Legacy Financial Solutions LLC 在第二季度收购了 BioCryst 制药的新股份，价值约 72,000 美元。对冲基金和其他机构投资者持有该公司 85.88% 的股票。</p>
</div><h2>BioCryst Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>BioCryst 制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.</p>
<div class="lb-trans"><p>BioCryst 制药公司是一家生物技术公司，开发口服小分子和蛋白质治疗药物以治疗罕见疾病。该公司销售 peramivir 注射液，这是一种用于治疗急性非复杂流感的静脉注射神经氨酸酶抑制剂，品牌名为 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及 ORLADEYO，一种用于治疗遗传性血管性水肿的口服丝氨酸蛋白酶抑制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than BioCryst Pharmaceuticals</li>
<li>Following Congress Stock Trades</li>
<li>3 Long-Term Dividend Buys You Can Get for Under $50</li>
<li>Should You Invest in Penny Stocks?</li>
<li>How AEP Became a Critical AI Infrastructure Play</li>
<li>What is a Death Cross in Stocks?</li>
<li>How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 BioCryst 制药更好</li>
<li>国会股票交易跟踪</li>
<li>3 只长期分红股票，价格低于 50 美元</li>
<li>你应该投资于便士股票吗？</li>
<li>AEP 如何成为关键的 AI 基础设施投资</li>
<li>股票中的死亡交叉是什么？</li>
<li>彼得·蒂尔支持的加密交易所 Bullish 的 IPO 进展如何？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BioCryst 制药吗？</h2>
</div><p>Before you consider BioCryst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 BioCryst 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 BioCryst 制药并不在名单上。</p>
</div><p>While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioCryst 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Theresa Heggie 出售了 BioCryst 制药公司（NASDAQ:BCRX）70,000 股股票